기업
Genexine, Chairman Young Chul Sung “Resigning from the CEO and Board of Directors”
by Sungmin Kim
“Building a professional management team system, focusing on the COVID-19 vaccine in a technology team”
Genexine said on the 14th that Chairman Young chul Sung will step down from the management front. Chairman Sung will step down from the board of directors as well as CEO. However, it will be maintained until September 1st to establish a next-generation professional management system that will lead Genexine.
The reason Genexine ostensibly announced the resignation of Chairman Sung from the front line is that it "will focus on developing the COVID-19 vaccine ‘GX-19N' and original technology for a gene vaccine. To this end, Chairman Sung will remain at Genexine as a technology team’s manager and focus on his area of expertise, science and technology development.
The reasons that Chairman Young-chul Sung directly stated are as follows.
“I will go back to the beginning when I set the name of Genexine by adding the meanings of Gene and Vaccine, and I will step down from the front line of business and focus on developing a COVID-19 preventive vaccine and securing the original technology for a gene vaccine. This is essential not only for Genexine, but also for society and the nation, and it is the most valuable thing that can be done now.”
According to the company, Genexine is currently conducting 24 clinical trials by promoting open innovation such as joint research, joint development, and joint clinical trials as a C&D (connect & development) model. In addition, at the end of last year, the total assets exceeded 500 billion won, becoming a medium-sized company, and the investment assets available for disposal also exceeded 900 billion won.
Genexine said, "More global C&D projects need to be carried out in the future, and for this, we plan to establish a professional management system and entrust the management to professional managers, and Chairman Sung will focus on science and technology development."
Regarding the timing of the introduction of the professional management system, Genexine explained, "The company has grown into a R&D-oriented company since its establishment." "Now is the most suitable time for Genexine to take a second leap forward as a global company."
